4.7 Article

Chiral polymer modified nanoparticles selectively induce autophagy of cancer cells for tumor ablation

Journal

JOURNAL OF NANOBIOTECHNOLOGY
Volume 16, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s12951-018-0383-9

Keywords

Nanomaterials; Chiral polymer; Cytotoxicity; Autophagy; Tumor ablation

Funding

  1. Science and Technology Innovation Plan of Southwest Hospital [SWH2016JCYB-04, SWH2016YSCXZD-10]
  2. Third Military Medical University Foundation [2016XPY12]
  3. Natural Science Foundation of China [51703243, 30700814]

Ask authors/readers for more resources

Background: Autophagy regulation through exogenous materials has aroused intensive attention to develop treatment protocols according to diverse human diseases. However, to the best of our knowledge, few examples have been reported to selectively control autophagy process and ultimately achieve efficient therapeutic potential. Results: In this study, monolayers of poly (acryloyl-L, D and racemic valine) (L-PAV-AuNPs, D-PAV-AuNPs and L/D-PAV-AuNPs) chiral molecules were anchored on the surfaces of gold nanoparticles (PAV-AuNPs), and the subsequent chirality-selective effects on autophagy activation were thoroughly studied. The cytotoxicity induced by PAV-AuNPs towards MDA-MB-231 cells (Breast cancer cells) was achieved mainly through autophagy and showed chirality-dependent, with D-PAV-AuNPs exhibiting high autophagy-inducing activity in vitro and in vivo. In contrast, the PAV-AuNPs exhibited autophagy inactivation for normal cells, e.g., 3T3 fibroblasts and HBL-100 cells. The chirality-selective autophagy activation effect in MDA-MB-231 cells was likely attributed to the chirality-variant ROS generation, cellular uptake and their continuous autophagy stimulus. Furthermore, the intratumoral injection of D-PAV-AuNPs could largely suppress the tumor growth but exhibit negligible toxicity in vivo. Conclusions: As the first exploration on stereospecific NPs for autophagy induction, this work not only substantiates that chiral polymer coated NPs can selective induce autophagy-specific in cancer cells and achieve a high tumor eradication efficiency in vivo, but also opens up a new direction in discovering unprecedented stereospecific nanoagents for autophagy-associated tumor treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer

Qiyun Shi, Juncheng Xuhong, Tao Luo, Jia Ge, Feng Liu, Yang Lan, Qingqiu Chen, Peng Tang, Linjun Fan, Li Chen, Yan Liang, Minghao Wang, Ying Hu, Yi Zhang, Xiuwu Bian, Xiaowei Qi, Jun Jiang

Summary: The study suggests that activating mutations in PIK3CA are associated with a reduced response to neoadjuvant therapy with pyrotinib and trastuzumab in HER2-positive breast cancer. Wild-type PIK3CA patients had a significantly higher pCR rate compared to mutated PIK3CA patients. The integrated model showed a high predictive value.

BRITISH JOURNAL OF CANCER (2023)

Article Surgery

Association of Long-term Oncologic Prognosis With Minimal Access Breast Surgery vs Conventional Breast Surgery

Andi Wan, Yan Liang, Li Chen, Shushu Wang, Qiyun Shi, Wenting Yan, Xiaozhen Cao, Ling Zhong, Linjun Fan, Peng Tang, Guozhi Zhang, Siyi Xiong, Cheng Wang, Zhen Zeng, Xiujuan Wu, Jun Jiang, Xiaowei Qi, Yi Zhang

Summary: This retrospective cohort study found that long-term therapeutic outcomes following minimal access breast surgery (MABS) were not significantly different from conventional breast surgery (CBS) in patients with early-stage breast cancer.

JAMA SURGERY (2022)

Article Oncology

A novel pyroptosis-related indicator of immune infiltration features and prognosis in breast cancer

Cheng Wang, Liyong Zhang, Lin Ren, Guozhi Zhang, Andi Wan, Siyi Xiong, Hao Tian, Zaihui Peng, Tingting Zhao, Pingping Gao, Na Sun, Yi Zhang, Xiaowei Qi

Summary: Cell pyroptosis is closely associated with breast cancer, and a prognostic model based on cell-pyroptosis-related genes provides innovative insights into the prognosis and treatment of breast cancer.

FRONTIERS IN ONCOLOGY (2022)

Review Biochemistry & Molecular Biology

Predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors: A systematic review and meta-analysis

Qiyun Shi, Juncheng Xuhong, Hao Tian, Man Qu, Yi Zhang, Jun Jiang, Xiaowei Qi

Summary: This systematic review and meta-analysis study examines the predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with TKIs. The analysis of 17 studies involving 1706 patients shows that wild-type PIK3CA patients had higher complete response rates and objective response rates compared to mutated PIK3CA patients. Additionally, PIK3CA mutations were marginally associated with poorer progression-free survival and overall survival in metastatic breast cancer patients. Therefore, PIK3CA mutations can predict treatment response in HER2-positive breast cancer patients treated with TKI-containing regimens.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2023)

Article Biotechnology & Applied Microbiology

A redox-reactive delivery system via neural stem cell nanoencapsulation enhances white matter regeneration in intracerebral hemorrhage mice

Xuejiao Lei, Quan Hu, Hongfei Ge, Xuyang Zhang, Xufang Ru, Yujie Chen, Rong Hu, Hua Feng, Jun Deng, Yan Huang, Wenyan Li

Summary: This study successfully addresses two challenges in neural stem cell transplantation therapy for intracerebral hemorrhage - low survival rate and uncontrolled differentiation - by designing a nanogel system, promoting white matter regeneration and improving behavioral performance in ICH mice.

BIOENGINEERING & TRANSLATIONAL MEDICINE (2023)

Article Pharmacology & Pharmacy

High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database

Pan Ma, Hao Tian, Qiuling Shi, Ruixiang Liu, Yi Zhang, Xiaowei Qi, Yongchuan Chen

Summary: Through the analysis of the FDA Adverse Event Reporting System database, it was found that T-DXd and T-DM1 have differences in adverse events. T-DXd is more likely to induce ILD/pneumonia and myelosuppression, while T-DM1 has a higher risk of hepatotoxicity, cardiotoxicity, and thrombocytopenia. Clinicians need to balance the treatment benefits and risks of antibody-drug conjugates in the treatment of HER2-positive breast cancer and HER2-mutated lung cancer.

EXPERT OPINION ON DRUG SAFETY (2023)

Article Oncology

Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations

Hao Tian, Man Qu, Guozhi Zhang, Long Yuan, Qiyun Shi, Yinhuan Wang, Ying Yang, Yi Zhang, Xiaowei Qi

Summary: This case report describes the successful treatment of invasive lobular breast cancer carrying HER2 mutations with combined treatment involving the tyrosine kinase inhibitor pyrotinib and the antibody-drug conjugate ado-trastuzumab emtansine. The combination therapy showed promising efficacy and may be a potential treatment option for HER2-mutated advanced breast cancer. Further studies are needed to validate these findings.

ONCOLOGIST (2023)

Article Materials Science, Biomaterials

A CO-mediated photothermal therapy to kill drug-resistant bacteria and minimize thermal injury for infected diabetic wound healing

Xin Jin, Zelin Ou, Guowei Zhang, Rong Shi, Jumin Yang, Wenguang Liu, Gaoxing Luo, Jun Deng, Wei Wang

Summary: With the rise of drug-resistant bacteria, photothermal therapy (PTT) is a promising solution for treating infected diabetic skin ulcers. However, tissue damage caused by heat limits its clinical application. A CO-mediated PTT agent (CO@mPDA) was developed to inhibit bacterial growth and promote tissue regeneration. The CO-mediated PTT exhibited higher efficacy in inhibiting drug-resistant bacteria and lower heat resistance in mammalian tissues. It also upregulated tissue-protective proteins to reduce thermal injury. This approach offers a potential way to enhance PTT efficiency and minimize side effects when treating infected skin wounds.

BIOMATERIALS SCIENCE (2023)

Article Oncology

A multi-center cross-sectional investigation of the diagnosis and treatment of breast cancer with synchronous ipsilateral supraclavicular lymph node metastases based on the CSBrs-009

Xiang Ai, Peng Sun, Minghao Wang, Peng Tang, Jinping Liu, Jun Jiang

Summary: This study aimed to determine the current status of the diagnosis and treatment of breast cancer with ipsilateral supraclavicular lymph node metastases (ISLM) among Chinese patients. The study found a low overall detection rate of ISLM breast cancer in China and a lack of consensus on the optimal diagnosis and treatment strategies for these patients.

CLINICAL & TRANSLATIONAL ONCOLOGY (2023)

Article Oncology

Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations

Hao Tian, Man Qu, Guozhi Zhang, Long Yuan, Qiyun Shi, Yinhuan Wang, Ying Yang, Yi Zhang, Xiaowei Qi

Summary: HER2 signaling is activated in response to somatic HER2 mutations, which are associated with poor prognosis in invasive lobular breast cancer (ILC). Tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) have shown promising efficacy in patients with HER2-mutated advanced breast cancer (BC). A case study suggests that a combination of irreversible TKIs and ADCs may be a potential treatment option for HER2-negative/HER2-mutated advanced BC.

ONCOLOGIST (2023)

Article Chemistry, Analytical

Graphene Oxide-Based Highly Sensitive Assay of Circulating MicroRNAs for Early Prediction of the Response to Neoadjuvant Chemotherapy in Breast Cancer

Zhijia Li, Hongtao Xiao, Junjie Li, Zhongzhu Yang, Jun Jiang, Juan Ji, Cheng Peng, Yang He

Summary: The response to neoadjuvant chemotherapy in breast cancer patients is crucial for their survival. Current techniques for predicting the efficacy of chemotherapy in these patients have limitations in sensitivity and specificity. We developed a highly sensitive method using graphene oxide for early prediction of chemotherapy efficacy in breast cancer patients.

ANALYTICAL CHEMISTRY (2022)

Article Oncology

A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer

Min Yan, Peng Yuan, Quchang Ouyang, Ying Cheng, Guohui Han, Dewei Wang, Li Ran, Tao Sun, Da Zhao, Yuju Bai, Shun'e Yang, Xiaojia Wang, Rong Wu, Xiaohua Zeng, Herui Yao, Xuening Ji, Jun Jiang, Xiaohua Hu, Haifeng Lin, Liping Zheng, Zhitu Zhu, Wei Ge, Junlan Yang, Tongjian Cui, Xiaozhi Zhang, Fangyang Lu, Wenhui Li, Hongyan Xu, Mafei Kang, Ping Gong, Liqun Zou, Jiang Liu, Hongliang Zhang, Hao Yu, Binghe Xu

Summary: This study evaluated the efficacy and safety of lobaplatin-based chemotherapy in Chinese patients with metastatic breast cancer. The results showed that lobaplatin-based chemotherapy had favorable efficacy and manageable safety profile in advanced breast cancer patients.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

No Data Available